Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study

Authors:

Abstract
Introduction: Amisulpride appears to be an effective atypical agent for treating schizophrenia in a dose-dependent manner. Methods: 29 patients suffering from schizophrenia or schizoaffective disorder were treated with a broad dose range of amisulpride (50–1 200 mg/day, mean: 455.2±278.8 mg/day). After 2 weeks, brain single photon emission tomography (SPET) scans were performed two hours after intravenous injection of 185 MBq [123I]IBZM. Clinical evaluations and ratings of extrapyramidal symptoms were performed at baseline and after steady state treatment of two weeks with amisulpride. Results: In patients treated with amisulpride, specific binding of [123I]IBZM to D2 receptors was significantly decreased (pDiscussion: Within the first two weeks of treatment with the atypical antipsychotic amisulpride a significant occupancy of striatal postsynaptic dopamine D2 receptors was achieved. At the same time amisulpride shows an excellent tolerability with good efficacy.